Jul 9, 2020 7:30 am EDT Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial Officer
Jul 8, 2020 7:30 am EDT Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies
Jun 18, 2020 7:30 am EDT Abeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual Meeting
Jun 17, 2020 7:30 am EDT Abeona Therapeutics Further Strengthens Board with Appointment of Two New Independent Directors
May 28, 2020 8:30 am EDT Abeona Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
May 6, 2020 4:14 pm EDT Abeona Therapeutics Reports First Quarter Financial Results and Business Updates
Apr 21, 2020 4:04 pm EDT Abeona Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Apr 21, 2020 8:00 am EDT Abeona Therapeutics Appoints Brian Pereira and Shawn Tomasello to the Board of Directors
Mar 17, 2020 7:30 am EDT Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
